NASDAQ, page-22

In the end its extremely positive just to have someone planning to further CVAC. Sure other scenarios were preferable but considering its longer than a year since the big spike and we are now focusing elsewhere it makes sense to at least try this and maybe generate something from an otherwise shelved treatment. I'd be surprised if there were other big name suitors as the stench that was Dendreon will have scared many interested in this off. I'd love to be proven wrong and this cause a rerate, I just think it's unlikely since any value from it could be years off and it's still a big if.